Amplia Therapeutics Limited (ATX.AX)
ASX - ASX Delayed price. Currency in AUD
Add to watchlist
At close: 04:10PM AEST
| Previous close | 0.0600 |
| Open | 0.0600 |
| Bid | 0.0580 x 3463500 |
| Ask | 0.0600 x 4114300 |
| Day's range | 0.0600 - 0.0600 |
| 52-week range | 0.0550 - 0.0950 |
| Volume | |
| Avg. volume | 107,869 |
| Market cap | 11.64M |
| Beta (5Y monthly) | 0.56 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0200 |
| Earnings date | 28 May 2024 - 03 Jun 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireFDA CLEARANCE OF AMPLIA'S IND FOR PANCREATIC CANCER TRIAL IN US
Amplia Therapeutics Limited (ASX: ATX), ("Amplia" or the "Company"), is pleased to announce that the US FDA have cleared Amplia's IND application for a trial of Amplia's best-in-class focal adhesion kinase (FAK) inhibitor narmafotinib in pancreatic cancer. The proposed trial will explore the safety, tolerability and efficacy of a combination of narmafotinib with the chemotherapy regime FOLFIRINOX.
© 2024 Yahoo. All rights reserved.